Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Lifecore Biomedical (LFCR) over the last 14 years, with May 2025 value amounting to $8.3 million.

  • Lifecore Biomedical's Cash & Current Investments fell 2.33% to $8.3 million in Q2 2025 from the same period last year, while for May 2025 it was $31.6 million, marking a year-over-year decrease of 13.29%. This contributed to the annual value of $8.3 million for FY2025, which is 2.33% down from last year.
  • As of Q2 2025, Lifecore Biomedical's Cash & Current Investments stood at $8.3 million, which was up 52.58% from $5.4 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Cash & Current Investments ranged from a high of $19.1 million in Q2 2023 and a low of $609,000 during Q4 2021.
  • Moreover, its 3-year median value for Cash & Current Investments was $8.4 million (2024), whereas its average is $8.9 million.
  • As far as peak fluctuations go, Lifecore Biomedical's Cash & Current Investments plummeted by 75.40% in 2021, and later surged by 1,826.44% in 2023.
  • Over the past 5 years, Lifecore Biomedical's Cash & Current Investments (Quarterly) stood at $609,000 in 2021, then surged by 875.04% to $5.9 million in 2022, then spiked by 1,826.44% to $19.1 million in 2023, then crashed by 55.68% to $9.5 million in 2024, then decreased by 2.33% to $8.3 million in 2025.
  • Its Cash & Current Investments was $8.3 million in Q2 2025, compared to $5.4 million in Q1 2025 and $9.5 million in Q4 2024.